"Abiraterone Acetate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.
| Descriptor ID |
D000069501
|
| MeSH Number(s) |
D04.210.500.054.079.065
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Abiraterone Acetate".
Below are MeSH descriptors whose meaning is more specific than "Abiraterone Acetate".
This graph shows the total number of publications written about "Abiraterone Acetate" by people in this website by year, and whether "Abiraterone Acetate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Abiraterone Acetate" by people in Profiles.
-
[Update on the risk of corticosterone therapy in combination with abiraterone acetate during the COVID-19 pandemic]. Prog Urol. 2021 04; 31(5):243-244.
-
Re: Thomas Loubersac, Molière Nguile-Makao, Frédéric Pouliot, Vincent Fradet, Paul Toren. Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study. Eur Urol Oncol 2020;3:298-305. Eur Urol Oncol. 2020 06; 3(3):391.
-
Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era. Cancer Treat Rev. 2019 Mar; 74:35-42.
-
The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel? Future Oncol. 2017 Dec; 13(30):2785-2790.
-
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2017 04; 71(4):630-642.